Biovitrum, Wyeth Extend Supply Pact

Biovitrum AB and Wyeth have extended their ReFacto supply agreement through December 31, 2015. Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto, as well as Xyntha/ReFacto AF, the successor products, and will continue to receive royalties from Wyeth’s global sales. Biovitrum’s co-promotion rights in the Nordic region remain unchanged. Biovitrum’s total revenues from the ReFacto business amounted to $143 million in 2007. ReFacto, Xyntha and ReFacto AF are recombinant protein drugs for hemophilia A.

“We are very pleased to be able to announce the prolongation of our long and successful collaboration with Wyeth. The agreement enables us to together provide the new improved Xyntha and ReFacto AF internationally, and to improve the lives of hemophilia patients.” commented Martin Nicklasson, chief executive officer of Biovitrum. “The agreement validates our biotechnology therapeutic production capabilities and expertise.”